Ligand CLO, Secretary Andrew Reardon reports disposal of 5,000 common shares worth $1.44 million
Reuters2026/08/04 22:43- Ligand Pharmaceuticals CLO and Secretary Andrew Reardon exercised employee stock options for 5,000 shares at USD 52.27 on Aug. 3.
- He sold 5,000 shares on Aug. 3 at prices mostly around USD 284–293.
- Directly owned common stock ended at 41,514 shares.
- Employee stock options held ended at 29,444.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y
As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
Crypto prices
More
